Pfenex, Inc. and Cedarlane have entered into a non-exclusive distribution agreement under which Cedarlane will market and distribute Pfenex reagent proteins to researchers in the U.S. and Canada. The products will include vaccine carrier proteins such as CRM197 and Cholera Toxin B, and cell culture-related growth factors including G-CSF and Interferon beta 1-b. New products developed by Pfenex will be added upon launch.
Patrick K. Lucy, vice president, business development at Pfenex, remarked, "Leveraging the Pfenex Expression Technology platform, we are now producing and making available complex reagent proteins to meet the needs of the biotech R&D and clinical development community. As Pfenex grows its reagent proteins business, we welcome the opportunity to work with world-class distributors such as Cedarlane to enable placing Pfenex products in the hands of life science researchers around the world."
"Cedarlane is proud to add Pfenex Inc. products to its extensive portfolio," said John Course, Cedarlane vice president. "Canadian scientists have an even greater opportunity to consolidate their ordering from a long list of high-quality suppliers of scientific reagents." Key components of the Cedarlane mission are to provide quality products, assure the highest in customer satisfaction and respond to the dynamic needs of every research community.
Pfenex, Cedarlane Establish Distribution Pact
Published August 25, 2010
blog comments powered by Disqus